Rx Propellant’s 3GV Campus in Genome Valley, Hyderabad secures prestigious LEED Gold Certification

IMT News Desk
IMT News Desk
· 3 min read

The LEED Gold certification underscores 3GV’s focus on energy efficiency, water conservation, and healthy indoor environments

Rx Propellant, an Actis Platform, has announced that its state-of-the-art life sciences campus, 3GV in Genome Valley, Hyderabad, has been awarded the LEED Gold Certification — one of the world’s most respected benchmarks for sustainable building design. The recognition highlights its commitment to creating infrastructure that not only empowers scientific progress but also sets new standards for environmental responsibility.

The LEED Gold certification underscores 3GV’s focus on energy efficiency, water conservation, and healthy indoor environments — qualities that directly benefit life sciences companies. By reducing operating costs, strengthening ESG credentials, and offering healthier workspaces, the campus provides an ecosystem where innovation and sustainability move in tandem.

This milestone builds on 3GV’s earlier achievement in 2024, when it became the world’s first IFC EDGE Advanced-certified speculative life sciences building. Together, these recognitions place 3GV at the forefront of sustainable scientific infrastructure globally, showcasing Rx Propellant’s ability to deliver pioneering campuses that meet the highest international standards.

Awarded by the US Green Building Council (USGBC), LEED (Leadership in Energy and Environmental Design) is the world’s most widely recognised green building certification. Projects are evaluated across parameters such as energy performance, water efficiency, materials selection, waste management, site sustainability, and indoor environmental quality. Achieving a Gold rating places 3GV among the top-performing buildings globally in terms of environmental impact, operational efficiency, and occupant well-being.

Praveen Kumar, Principal, Real Estate, Actis, said, “The LEED Gold certification for 3GV is a milestone that reflects our vision of building sustainable, future-ready campuses for the life sciences sector. At Actis, we believe that responsible investments must deliver long-term value to both our partners and the planet. With 3GV, we are enabling pharma and biotech companies to innovate in an environment that is energy-efficient, climate-resilient, and aligned with high global standards.”

Phani Rama Krishna, Senior Vice President – ESG, added, “From resource conservation to occupant well-being, the certification validates our efforts to minimize environmental impact while maximising operational efficiency. For life sciences companies, this means predictable costs, reduced environmental risks, and a stronger ESG profile — all of which are becoming increasingly critical in global partnerships and investor conversations.”

Shami Nissan, Partner and Managing Director, Sustainability at Actis, said, “This certification is globally significant because it demonstrates that India can combine world-class science infrastructure with sustainability at scale. Around the world, life sciences organisations are under pressure to cut carbon emissions and improve resilience, while still driving innovation at speed. 3GV shows how these goals can coexist. It sets a benchmark for how sustainable design and smart operations can empower companies to expand responsibly while contributing to a greener future.”

With this achievement, Rx Propellant continues to shape the next generation of life sciences infrastructure in India. 3GV now stands as a symbol of how sustainability and scientific excellence can go hand in hand — helping companies working there become not only future-focused but also future-proof.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk